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Summary
To investigatewhether phosphatidylinositol-3 kinase (PI3K) signalingmediates themetabolic effectsof hypothalamic leptin ac-
tion, adenoviral gene therapywas used to direct expression of leptin receptors to the area of the hypothalamic arcuate nucleus
(ARC). This intervention markedly improved insulin sensitivity in genetically obese, leptin-receptor-deficient Koletsky (fak/fak)
rats via amechanism thatwas not dependent on reduced food intake butwas attenuatedbyw44%by third-ventricular infusion
of thePI3K inhibitor LY294002. Conversely, ARC-directed expression of a constitutively activemutant of protein kinaseB (PKB/
Akt, an enzyme activated by PI3K)mimicked the insulin-sensitizing effect of restored hypothalamic leptin signaling in these an-
imals, despite having no effect on food intake or body weight. These findings suggest that hypothalamic leptin signaling is an
important determinant of glucose metabolism and that the underlying neuronal mechanism involves PI3K.Introduction
In addition to its role in energy homeostasis, the adipocyte hor-
mone leptin is strongly implicated in the regulation of glucose
metabolism. This assertion is supported by the observation
that, in rodent models, genetic leptin deficiency causes severe
insulin resistance and diabetes, in addition to hyperphagia and
obesity (Seidman et al., 1967; Zhang et al., 1994), and that the
ability of leptin to lower plasma glucose and insulin levels can
readily be dissociated from its effects on body weight (Pelley-
mounter et al., 1995; Schwartz et al., 1996b; Shimomura et al.,
1999). Similarly, leptin deficiency is implicated in the severe in-
sulin resistance and diabetes characteristic of lipodystrophy
syndromes (Oral et al., 2002; Petersen et al., 2002; Shimomura
et al., 1998) since leptin treatment ameliorates these metabolic
disorders in both humans and mouse models of this disease
(Oral et al., 2002; Petersen et al., 2002; Shimomura et al.,
1999). Moreover, administration of leptin into the third ventricle
reverses the insulin-resistance and diabetes phenotypes of
lipodystrophic mice at low doses that are ineffective when ad-
ministered peripherally (Asilmaz et al., 2004). Combined with ev-
idence that hyperglycemia and hyperinsulinemia are amelio-
rated by restoration of leptin receptors to the hypothalamic
arcuate nucleus (ARC) of mice that otherwise lack these recep-
tors (Coppari et al., 2005), these data are compatible with a
growing literature (Obici et al., 2002a, 2002b; Pocai et al., 2005)
that implicates the ARC in adaptive changes of glucose metab-
olism in response to afferent input from hormonal and nutrient-
related signals, including insulin, leptin, and long-chain free fatty
acids.
Although the intracellular signal transduction mechanisms
that transduce afferent input to the ARC into adaptive changes
of insulin sensitivity remain to be delineated, several findings im-CELL METABOLISM : DECEMBER 2005 $ VOL. 2 $COPYRIGHT ª 2005 Eplicate the insulin receptor substrate (IRS)-phosphatidylinositol-
3-OH kinase (PI3K) pathway in this process. Both leptin and in-
sulin activate this pathway in hypothalamic neurons (Niswender
et al., 2001, 2003; Spanswick et al., 1997; Xu et al., 2005) and
other tissues (Berti et al., 1997; Cohen et al., 1996). Furthermore,
knockout of IRS2 from hypothalamic neurons predisposes to
insulin resistance, glucose intolerance, obesity, and diabetes
(Kubota et al., 2004; Lin et al., 2004). Combined with the obser-
vation that leptin regulation of glucose metabolism (but not
food intake or body weight) involves a mechanism independent
of STAT3 signaling (Bates et al., 2005), convergent evidence
supports a model in which hypothalamic signal transduction
via IRS-PI3K is a key determinant of peripheral-tissue insulin
sensitivity.
In the current work, we studied Koletsky (fak/fak) rats that de-
velop obesity, hyperphagia, glucose intolerance, and insulin re-
sistance due to genetic absence of all leptin-receptor protein
(Ernsberger et al., 1999; Takaya et al., 1996). We hypothesized
that if reduced leptin signaling in the ARC of these animals con-
tributes to their impaired glucose metabolism, expression of
leptin receptors directed to this brain area should improve their
insulin resistance and that this effect should occur, at least in
part, independently of changes of food intake and body weight.
We further hypothesized that if neuronal IRS-PI3K signaling
plays a key role in mediating this leptin effect, the response to
leptin-receptor gene therapy should be attenuated by blockade
of neuronal PI3K signaling. Conversely, the response to restored
leptin signaling in the area of the ARC should be mimicked
by leptin-independent activation of PI3K in this brain area. To
test these hypotheses, we employed an established adenoviral
gene therapy technique to direct expression of the ‘‘long’’ or
‘‘signaling’’ form of the leptin receptor (leprb) or a constitutively
active (CA) mutant of PKB (Akt, a key downstream mediator ofLSEVIER INC. DOI 10.1016/j.cmet.2005.10.009 411
A R T I C L EFigure 1. Insulin sensitivity and glucose tolerance in
lean (Fa/Fa) and obese (fak/fak) rats
A and B) Fasting blood glucose (A) and plasma insu-
lin levels (B) in lean (Fa/Fa) and obese (fak/fak) rats.
C and D) Insulin tolerance (2 U/kg) (C) and the in-
verse integrated area under the glucose curve (In-
verse AUCglucose) (D) of Fa/Fa and fa
k/fak rats.
E and F) Intraperitoneal glucose tolerance (2.5 g/kg)
(E) and the integrated area under the glucose curve
(AUCglucose) (F) of Fa/Fa and fa
k/fak rats. *p < 0.05
versus Fa/Fa.PI3K signal transduction) to the area of the ARC of Koletsky rats.
Our results demonstrate that restored hypothalamic leptin sig-
naling in these animals markedly improved insulin sensitivity in
peripheral tissues and that this effect involves neuronal signal
transduction via the IRS-PI3K pathway. Indeed, activation of
signaling downstream of PI3K in this brain area improved insulin
sensitivity even in the absence of a leptin signal.
Results
Insulin sensitivity and glucose tolerance of fak/fak
and Fa/Fa rats
Consistent with previous reports (Koletsky, 1973), fasting blood
glucose levels in male fak/fak rats were similar to those of lean
Fa/Fa littermates, yet plasma insulin levels were increased by
>3-fold (1256 6 162 versus 328 6 88 pmol/l; p < 0.05) (Figures
1A and 1B), suggesting profound insulin resistance. To assess
insulin sensitivity more directly, we performed insulin-tolerance
tests (itt; 2 U/kg) in both groups. Again, fasting blood glucose
levels were normal in both genotypes (85.4 6 2.4 versus
84.2 6 1.5 mg/dl; p = ns), but the ability of insulin (2 U/kg intra-
peritoneally [i.p.]) to reduce blood glucose levels was markedly
impaired in fak/fak rats relative to their lean littermates (inverse
AUCglucose: 1292 6 365 versus 4925 6 279 mg/dl/120 min;
p < 0.05) (Figures 1C and 1D). This reduction of insulin sensitivity
in obese fak/fak rats was accompanied by a marked impairment
of glucose tolerance relative to Fa/Fa rats, reflected by a >3-fold
increase in the area under the glucose curve (AUCglucose: 88826
1119 versus 2421 6 709 mg/dl/120 min; p < 0.05) (Figures 1E412and 1F) during an intraperitoneal glucose-tolerance test (i.p.
gtt) (2.5 g/kg).
To investigate whether the insulin resistance of fak/fak rats de-
pends upon their hyperphagia and increased body weight, we
next compared insulin tolerance of Fa/Fa to fak/fak animals
that were either fed ad libitum or were restricted to 60% of their
daily food intake for a 2 week period (fak/fak-FR) (Figure 2A). This
intervention resulted in a body weight similar to that of Fa/Fa
controls (Fa/Fa-AL) (305 6 7 versus 323 6 14 g; p = ns) (n = 7/
group), while fak/fak rats fed ad libitum (fak/fak-AL) were signifi-
cantly heavier (4106 7 g; p < 0.05 for each) (Figure 2B). The abil-
ity of insulin (0.75 U/kg) to reduce blood glucose levels
was markedly attenuated in fak/fak rats relative to Fa/Fa-AL ani-
mals regardless of whether they were food restricted (Inverse
AUCglucose: 5607 6 307 for Fa/Fa-AL versus 2615 6 504 for
fak/fak-AL versus 2260 6 152 for fak/fak-FR mg/dl/120 min; p <
0.05) (Figures 2C and 2D). Therefore, hyperphagia is not
required for severe insulin resistance in rats lacking leptin
receptors.
Effect of ARC-directed leptin-receptor gene therapy
on insulin and glucose tolerance
To investigate whether reduced leptin action in the ARC contrib-
utes to impaired glucose metabolism in fak/fak rats, we mea-
sured insulin tolerance 7 days following bilateral microinjection
of an adenovirus expressing either leprb (Ad-LEPR-B) or a re-
porter gene (Ad-GFP) into the area of the ARC (n = 7–8/group).
To control for the ability of ARC-directed leptin-receptor gene
therapy to reduce food intake and body weight of fak/fak rats
(Morton et al., 2003), an additional group of fak/fak rats receivedCELL METABOLISM : DECEMBER 2005
Leptin regulates insulin sensitivity via PI3KFigure 2. Effect of 2 week food restriction on insulin tolerance in obese (fak/fak) rats
Food intake (A), body weight (B), insulin tolerance (0.75 U/kg) (C), and the inverse integrated area under the glucose curve (Inverse AUCglucose) (D) in Fa/Fa and fa
k/fak rats
fed ad libitum and fak/fak rats restricted to 60% of their daily food intake for 2 weeks. *p < 0.05 versus Fa/Fa-AL at day 14.the reporter gene Ad-GFP and were pair fed (Ad-GFP-PF) to the
intake of Ad-LEPR-B-treated animals (n = 8). By design, Ad-
GFP-PF and Ad-LEPR-B-treated animals experienced similar
weight loss over the first 7 days after adenoviral injection (D
body weight: 222.6 6 4.1 g versus 222.7 6 2.5 g; p = ns).
Whereas pair feeding did not significantly improve insulin toler-
ance compared to ad libitum-fed Ad-GFP-treated fak/fak rats,
the ability of insulin to lower blood glucose was increased
by 80% among fak/fak rats treated with Ad-LEPR-B (inverse
AUCglucose: 2839 6 337 for Ad-LEPR-B versus 1580 6 456 for
Ad-GFP fed ad libitum versus 1901 6 416 for Ad-GFP-PF
mg/dl/120 min; p < 0.05) (Figures 3A and 3B), representing an
estimated reversal by 31% of the ability of the fak/fak genotype
to cause insulin resistance. Therefore, ARC-directed leptin-re-
ceptor gene therapy improves insulin sensitivity via amechanism
that is, at least in part, independent of changes of food intake
and body weight.
Similarly, we found that ARC-directed Ad-LEPR-B treatment
significantly improved glucose tolerance measured on day 7
post adenoviral injection compared to ad libitum-fed Ad-GFP-
treated rats (AUCglucose: 6,932 6 651 versus 11,572 6
1,795 mg/dl/120 min; p < 0.05). Moreover, while glucose toler-
ance was also improved in pair-fed, Ad-GFP-treated controls,
the beneficial effect of Ad-LEPR-B treatment could not be fully
explained by reduced food intake or body weight, and, unlike
Ad-LEPR-B treated animals, the improvement in Ad-GFP-
treated Koletsky rats that were pair fed was not statistically
different from those that were fed ad libitum (AUCglucose:
11,572 6 1,795 versus 8,336 6 830 mg/dl/120 min; p = ns)
(Figure 3C).
To determine whether increased insulin secretion contributed
to the beneficial effect of Ad-LEPR-B treatment on glucose tol-
erance, wemeasured plasma insulin concentrations in the same
three groups of fak/fak rats at both baseline and the 30 min timeCELL METABOLISM : DECEMBER 2005point after glucose administration during the i.p. gtt. While
plasma insulin levels were comparable at baseline between
the three groups (and markedly elevated relative to Fa/Fa ani-
mals), theywere reduced at t = 30min in Ad-LEPR-B-treated an-
imals compared to either group that received Ad-GFP (3484 6
633 pmol/l for Ad-LEPR-B versus 5361 6 1056 pmol/l for
Ad-GFP versus 6020 6 1077 pmol/l for Ad-GFP-PF; p < 0.05),
a time when blood glucose levels were also reduced in this
group (Figure 3D). The improvement of glucose tolerance in
Ad-LEPR-B-treated fak/fak rats is therefore unlikely to be ex-
plained by increased insulin secretion. This interpretation is fur-
ther supported by the insulin sensitivity index (ISI, calculated
from the i.p. gtt data), which was increased in Ad-LEPR-B-
treated compared both to ad libitum- and pair-fed, Ad-GFP-
treated fak/fak rats (0.388 6 0.076 units for Ad-LEPR-B versus
0.177 6 0.026 units for Ad-GFP versus 0.133 6 0.040 units for
Ad-GFP-PF; p < 0.05). Together, these findings support the hy-
pothesis that the ability of restored hypothalamic leptin signaling
to improve glucose tolerance involves effects on insulin sensitiv-
ity rather than insulin secretion. Moreover, since basal plasma
insulin levels were not reduced by hypothalamic leptin-receptor
gene therapy, its effect on insulin sensitivity is more readily de-
tected in response to a dynamic increase of plasma insulin con-
centrations than in the fasted state.
We next sought to determine whether the effect of ARC-
directed leptin-receptor gene therapy might be explained, at
least in part, by changes in circulating lipids or hormones such
as glucocorticoids. To accomplish this, we measured plasma
triglyceride (TG) and free fatty acids (FFA) after a 4 hr fast and
corticosterone levels after an overnight fast. We found that, sim-
ilar to blood glucose and plasma insulin levels, plasma concen-
trations of TG, FFA, and corticosterone did not differ amongst
Koletsky rats treated with Ad-LEPR-B or Ad-GFP (p = ns)
(Table 1).413
A R T I C L EFigure 3. Effect of ARC-directed leptin-receptor gene therapy on insulin sensitivity and glucose tolerance in obese (fak/fak) rats
Insulin tolerance (2 U/kg) (A), the inverse integrated area under the glucose curve (Inverse AUCglucose) (B), glucose tolerance (C), and plasma insulin concentrations (D) in fa
k/
fak rats treated with either Ad-LEPR-B or Ad-GFP and fed ad libitum or Ad-GFP and pair fed (Ad-GFP-PF) at the same intake level as Ad-LEPR-B-treated rats. *p < 0.05
versus Ad-GFP; #p < 0.05 versus fak/fak Ad-LEPR-B.To determine the anatomical distribution of adenoviral gene
expression, brain sections were prepared for visualization of
GFP by fluorescence microscopy following ARC-directed mi-
croinjection of either Ad-GFP (n = 8) or Ad-LEPR-B-GFP (n =
4). This was conducted in a group of animals separate from
the cohort of animals that the metabolic studies were performed
on. As expected, we found that, for either adenoviral construct,
GFP was expressed in the ARC in all animals. Inw25% of ani-
mals, GFP expression was also detected along the cannula
tract, either just dorsal or ventral to the ARC, including cells in
the ventromedial nucleus (VMN) and medial eminence (ME).
However, expression of GFPwas not detected in any other brain
areas outside the mediobasal hypothalamus (including thala-
mus, hippocampus, and cortex), nor was it present in ependy-
mal cells lining the third ventricle (Figure 4).
Effect of central inhibition of PI3K on the
insulin-sensitizing effect of ARC-directed
leptin-receptor gene therapy
To determine whether the hypothalamic action of leptin to in-
crease insulin sensitivity in fak/fak rats involvesaPI3K-dependent
mechanism, we measured insulin tolerance in groups that had
undergone surgical placement of a chronic indwelling cannula
in the third ventricle at the time of Ad-LEPR-B or Ad-GFP micro-
injection into the ARC. One hour prior to the itt, animals treated
Table 1. Effect of ARC-directed leptin-receptor gene therapy on humoral factors
Ad-GFP Ad-LEPR-B Ad-GFP-PF
Glucose (mg/dl) 89.7 6 1.8 87.9 6 1.0 87.1 6 2.3
Insulin (pmol/l) 1252 6 329 1198 6 216 1711 6 570
Triglycerides (mg/dl) 244 6 44 201 6 25 230 6 23
FFA (mmol/l) 0.88 6 0.07 0.76 6 0.04 0.80 6 0.07
Corticosterone (ng/ml) 450 6 64 447 6 19 445 6 81414with either adenovirus received an intracerebroventricular
(i.c.v.) injection of either a PI3K inhibitor (LY294002; 1 nmol) or
its vehicle. Consistent with our previous observations, Ad-
LEPR-B-treated fak/fak rats exhibited a marked improvement
of insulin tolerance relative to those that received control adeno-
virus (inverse AUCglucose: 44986 305 versus 12866 510 mg/dl/
120 min; p < 0.05). While there was no significant effect of i.c.v.
LY294002 pretreatment on insulin tolerance in Ad-GFP-treated
animals (inverse AUCglucose: 1649 6 442 versus 1286 6 510
mg/dl/120 min; p = ns), third-ventricular injection of LY294002
attenuated the beneficial effects of Ad-LEPR-B on insulin tol-
erance by w44% (inverse AUCglucose: 3076 6 414 for Ad-
LEPR-B i.c.v. LY294002 versus 4498 6 305 for Ad-LEPR-B
i.c.v. vehicle mg/dl/120 min; p < 0.05) (Figures 5A–5C). In con-
trast, i.p. administration of the same dose of LY294002 was
without effect on insulin tolerance in fak/fak rats treated with
Ad-LEPR-B (Figure 5D), demonstrating that the deleterious ef-
fect of i.c.v. LY294002 in fak/fak rats following ARC-directed lep-
tin-receptor gene therapywas not due to leakage into theperiph-
ery. Moreover, i.c.v. pretreatment with LY294002 had no effect
on insulin tolerance in fak/fak rats receiving control adenovirus,
indicating that this drug does not have independent, deleterious
effects on insulin sensitivity.
Effect of increased hypothalamic PI3K signaling
on insulin sensitivity
The hypothesis that PI3K signaling is a downstream mediator of
the hypothalamic effects of leptin on glucose metabolism pre-
dicts that increased PI3K signaling in the area of the ARC of
fak/fak rats shouldmimic the effect of restored hypothalamic lep-
tin signaling. To test this hypothesis, adult male fak/fak rats re-
ceived ARC-directed microinjection of an adenovirus express-
ing either GFP or a CA mutant of PKB (Ad-PKB-CA), a keyCELL METABOLISM : DECEMBER 2005
Leptin regulates insulin sensitivity via PI3KFigure 4. Detection of adenovirally expressed genes
Expression of GFP following microinjection of either adenovirus expressing GFP in fak/fak rats fed ad libitum (Ad-GFP) (A) or pair fed (Ad-GFP-PF) (B) or adenovirus
expressing both leptin receptor and GFP in fak/fak rats fed ad libitum (Ad-LEPR-B-GFP) (C) using fluorescence microscopy. Magnification 103. 3V, third ventricle;
ARC, arcuate nucleus.enzyme activated by PI3K. Seven days following adenoviral
injection, fak/fak rats receiving Ad-PKB-CA exhibited a much
greater insulin-induced decline of blood glucose levels than
did Ad-GFP-treated animals (inverse AUCglucose: 2524 6 416
versus 1251 6 365 mg/dl/120 min; p < 0.05) (Figures 5E and
5F). While this improvement of insulin sensitivity was qualita-
tively similar to that induced in animals that received leptin-
receptor gene therapy, treatment with Ad-PKB-CA affected nei-
ther body weight (27.56 3.6 g versus25.06 3.7 g; p = ns) nor
mean daily food intake (22.26 1.0 g versus 23.36 0.9 g; p = ns)
relative to Ad-GFP-treated controls over a 12 day period follow-
ing adenoviral microinjection (Figures 5G and 5H). Thus, an
adenovirally induced increase of hypothalamic PKB signaling
recapitulates the effect of restored leptin signaling on insulin
sensitivity but not on energy balance.
Discussion
Growing evidence suggests that, in response to input from a va-
riety of hormonal and nutrient-related signals, hypothalamic
neuronal systems activate physiological responses that regulate
insulin sensitivity in peripheral tissues. The overarching concept
is that when the brain perceives a decline in levels of body en-
ergy stores or circulating nutrients, responses are triggered
that favor both positive energy balance and increased plasma
glucose levels. This concept has received extensive recent sup-
port from studies demonstrating that increased delivery of either
insulin or long-chain fatty acids to themediobasal hypothalamus
of normal rats increases hepatic insulin sensitivity (Obici et al.,
2002a, 2002b; Pocai et al., 2005), thereby reducing hepatic glu-
cose production (HGP) and lowering fasting plasma glucose lev-
els. Based on these observations and on similarities in the cen-
tral actions of leptin and insulin, we first tested the hypothesis
that reduced hypothalamic leptin signaling plays a key role
in the pathogenesis of the severe insulin resistance of leptin-
receptor-deficient Koletsky rats. Consistent with this hypothe-
sis, we found that, whereas insulin resistance of Koletsky rats
is not ameliorated by chronic caloric restriction and weightCELL METABOLISM : DECEMBER 2005loss, similar to recent findings in db/dbmice that lack functional
leptin receptors (Bates et al., 2005), restoration of leptin signal-
ing to the area of the ARC dramatically improved insulin sensi-
tivity of Koletsky rats via a mechanism that cannot be fully ex-
plained by reduced food intake or body weight. This finding
confirms and extends the recent observation of normalized
plasma glucose and insulin levels following restoration of leptin
signaling to the hypothalamus of leptin-receptor-deficient mice,
an effect that occurred despite comparatively modest reduc-
tions of food intake and body weight (Coppari et al., 2005).
In light of ample evidence that common forms of obesity are
associated with hypothalamic leptin resistance (El-Haschimi
et al., 2000; Munzberg et al., 2004; Van Heek et al., 1997;
Widdowson et al., 1997), delineating the neuronal signal trans-
duction mechanisms that mediate leptin regulation of glucose
metabolism is an important scientific priority from both a patho-
physiological and therapeutic perspective. The hypothesis that
signaling via the Jak-Stat pathway mediates leptin regulation
of glucose metabolism has been addressed indirectly using
mice in which the leptin-receptor gene is replaced with a mutant
allele that cannot activate STAT3 signaling. These animals ex-
hibit only a modest disorder of glucose homeostasis, despite
the severe hyperphagia and obesity that arise from the absence
of leptin-receptor-mediated activation of Jak-Stat signaling
(Bates et al., 2005). Indeed, chronic energy restriction of these
mice results in complete normalization of insulin sensitivity
(Bates et al., 2005), unlike mice lacking all leptin-receptor func-
tion (db/db), which exhibit severe insulin resistance and hyper-
glycemia even if hyperphagia is prevented (Bates et al., 2005;
Wyse and Dulin, 1970). Whereas STAT3 is required for leptin
regulation of energy homeostasis, therefore, leptin appears to
regulate glucose metabolism largely via a STAT3-independent
mechanism.
Recent studies suggest that hypothalamic IRS-PI3K signaling
is important in the control of both energy balance and glucose
metabolism (Choudhury et al., 2005; Kubota et al., 2004; Lin
et al., 2004). To determine whether neuronal IRS-PI3K signal-
ing is required for leptin regulation of glucose metabolism, we415
A R T I C L EFigure 5. Role of hypothalamic PI3K signaling in the action of leptin in the ARC on glucose metabolism
A–C) Insulin tolerance (2 U/kg) (A andC) and the inverse integrated area under the glucose curve (Inverse AUCglucose) (B) in Ad-LEPR-B- and Ad-GFP-treated fa
k/fak rats that
received a 1 hr i.c.v. pretreatment injection of either vehicle or the PI3K inhibitor LY294002 prior to the itt.
(D) Insulin tolerance in Ad-LEPR-B-treated fak/fak rats following a 1 hr pretreatment i.p. injection of either vehicle or the PI3K inhibitor LY294002.
E and F) Insulin tolerance (E) and the inverse integrated area under the glucose curve (Inverse AUCglucose) (F) of fa
k/fak rats studied 7 days after microinjection of either Ad-
GFP or Ad-PKB-CA directed to the ARC.
Gand H)Mean daily food intake (G) and body weight (H) 12 days following adenoviral microinjection of either Ad-GFP and Ad-PKB-CA. *p < 0.05 versus Ad-GFP; #p < 0.05
versus Ad-LEPR-B i.c.v. LY.infused LY294002, an inhibitor of PI3K, into the third ventricle of
Koletsky rats that had previously received leptin-receptor gene
therapy 1 hr prior to measurement of insulin sensitivity. Our find-
ing that the beneficial effect of restored hypothalamic leptin sig-
naling on insulin resistance was attenuated by i.c.v. pretreat-
ment with a PI3K inhibitor suggests a key role for PI3K in this
leptin effect. Conversely, we found that an adenovirally induced
increase of PKB signaling (a key enzyme downstream of PI3K) in
the area of the ARC of Koletsky rats recapitulates the metabolic416benefit conferred by restored leptin signaling in this brain region.
Although the predominant site of injection was the ARC, we de-
tected adenoviral expression along the cannula tract that in-
cluded adjacent hypothalamic structures in a minority of ani-
mals. As no expression was detected in areas outside of these
areas, however, consistent with our previous findings (Morton
et al., 2003, 2005), we conclude that the effect of hypothalamic
leptin signaling on insulin sensitivity involves mediobasal hypo-
thalamic signaling via the IRS-PI3K pathway and that increasedCELL METABOLISM : DECEMBER 2005
Leptin regulates insulin sensitivity via PI3Ksignaling via this transductionmechanism is sufficient to amelio-
rate insulin resistance even in the absence of a leptin signal.
These findings extend previous evidence of a key role for neu-
ronal IRS-PI3K signaling in the control of glucose metabolism.
For example, the hypothalamic action of insulin on HGP is
blocked by i.c.v. infusion of LY294002 (Obici et al., 2002b); in-
deed, i.c.v. infusion of this compound is in and of itself sufficient
to increase HGP in normal rats. By comparison, i.c.v. LY294002
did not detectably alter insulin sensitivity in Koletsky rats treated
with control adenovirus, presumably because both basal hypo-
thalamic signaling via PI3K and peripheral-tissue insulin sensi-
tivity are reduced in these animals. Since the beneficial effect
of ARC-directed leptin-receptor gene therapy on insulin sensi-
tivity in these animals was only partially reversed by pharmaco-
logical blockade of PI3K, however, PI3K-independent mecha-
nisms are also implicated in the glucoregulatory actions of
leptin in this brain area. Nonetheless, when combined with our
finding of improved insulin sensitivity in Koletsky rats receiving
ARC-directed microinjection of a constitutively active PKB
mutant, our data suggest that PI3K signaling in mediobasal hy-
pothalamus is both necessary and sufficient to explain a sub-
stantial portion of the hypothalamic action of leptin on glucose
metabolism.
It is worthwhile to note limitations inherent in the adenoviral
gene therapy technique employed here in the interpretation of
our findings. For example, although specific areas of rat brain
can be targeted with considerable accuracy, neither the specific
cell types that are transduced nor the level of expression of ad-
enovirally encoded genes in infected cells can be controlled.
Thus, it is conceivable that expression of leptin receptors is
higher in neurons from Koletsky rats transducedwith Ad-LEPRB
than normally occurs in leptin-receptor-expressing cells from
normal animals and that this affected study outcomes. How-
ever, we suspect that differences in receptor gene expression
have a minimal impact on our data since overexpression of
Ad-LEPRB in the hypothalamus of wild-type rats has no detect-
able effect on food intake, hypothalamic neuropeptide gene ex-
pression (Morton et al., 2003), or metabolic parameters.
The mechanism whereby hypothalamic leptin/PI3K signal-
ingmediates its effects on insulin sensitivity awaits further study.
Recent work from Pocai and colleagues (Pocai et al., 2005) sug-
gests that the hypothalamic action of insulin (which also de-
pends upon intact PI3K signaling) to regulate HGP involves a
descending pathway from hypothalamus to hindbrain that in
turn controls efferent vagal output to the liver. An alternative
and perhaps less likely possibility is that hypothalamic control
of insulin sensitivity involves changes in the plasma level of
nutrients such as FFA (Bergman and Ader, 2000) or hormones
such as glucocorticoids (Yu andGinsberg, 2005) that, in turn, af-
fect peripheral-tissue insulin action. However, we found no evi-
dence that ARC-directed leptin-receptor gene therapy alters
plasma levels of TG, FFA, or corticosterone. If a humoral mech-
anism mediates the metabolic actions of hypothalamic leptin
signaling, therefore, it appears to involve other, as yet unidenti-
fied, factors.
Our previous demonstration that the anorexic action of leptin
is dependent on neuronal PI3K signaling (since it is blocked by
i.c.v. pretreatment with a PI3K inhibitor) (Niswender et al.,
2001) seems paradoxical in light of our current finding that acti-
vation of hypothalamic PKB signaling in Koletsky rats improves
their insulin sensitivity while having no effect on the hyperphagiaCELL METABOLISM : DECEMBER 2005and weight gain that arises from deficient leptin signaling. One
interpretation of these results is that, whereas PI3K signaling
in the ARC is required for leptin regulation of both food intake
and glucose metabolism, it is sufficient to mediate only the latter
effect. Investigating this hypothesis and identifying the hypotha-
lamic neurons that transduce the leptin/PI3K signal into
changes of peripheral glucose metabolism or energy balance
are important priorities for future work. Of particular interest in
this context are ARC neurons that coexpress the orexigenic
peptides NPY and AgRP (Broberger et al., 1998; Hahn et al.,
1998). These neurons are inhibited by leptin and thus are acti-
vated in rodent models of impaired leptin signaling (Baskin
et al., 1999; Mercer et al., 1997; Mizuno and Mobbs, 1999;
Schwartz et al., 1996a), although the extent to which this effect
involves PI3K is uncertain. Indeed, leptin inhibition of hypotha-
lamicNpy and Agrp gene expression has been shown to require
intact PI3K signaling (Morrison et al., 2005), while recent evi-
dence suggests that, in mice, leptin regulation of IRS-PI3K sig-
naling in NPY/AgRP neurons occurs indirectly and is dependent
on synaptic transmission (Xu et al., 2005).
The hypothesis that activation of these neurons causes insulin
resistance is supported by evidence that i.c.v. infusion of NPY
increases plasma insulin and glucose levels (Zarjevski et al.,
1994; Zarjevski et al., 1993) and causes hepatic insulin resis-
tance even when its effects on food intake are prevented (van
den Hoek et al., 2004). Since leptin-receptor gene therapy di-
rected to the ARC reduces hypothalamic Npy mRNA levels
(Morton et al., 2003), reduced signaling by NPY/AgRP neurons
may contribute to the improvement of insulin sensitivity ob-
served in our studies. This hypothesis is further supported by ev-
idence that third-ventricular infusion of insulin, oleic acid (a long-
chain free fatty acid), or an inhibitor of fatty-acid oxidation (which
raises hypothalamic fatty-acyl CoA levels) reduces both food
intake and Npy mRNA content while also increasing hepatic in-
sulin sensitivity (Obici et al., 2002a, 2003).
The intimate coupling of glucose metabolism to changes of
food intake and body weight adds complexity to the interpreta-
tion of our studies since each of these parameters is sensitive to
the actions of leptin in the hypothalamus. Here, we cite four in-
dependent observations indicating that the effects of hypotha-
lamic leptin and PI3K signaling on glucose metabolism cannot
be attributed to changes of food intake or body weight. First,
the insulin resistance of fak/fak rats was not ameliorated by
chronic energy restriction, indicating that hyperphagia and pos-
itive energy balance are not sufficient to explain the severe insu-
lin resistance of animals that lack a leptin signal. Second, the
effect of leptin-receptor gene therapy on insulin sensitivity
was not detected in fak/fak rats that received the control adeno-
virus and were pair fed to animals receiving leptin-receptor
gene therapy. Third, i.c.v. infusion of the PI3K inhibitor
LY294002 acutely reversed the beneficial effects of hypotha-
lamic leptin signaling, despite the fact that feeding was not per-
mitted during this experiment. Finally, the effect of restored
hypothalamic leptin signaling on glucose metabolism was mim-
icked by increasing hypothalamic PKB signaling, despite having
no effect on food intake or body weight. Taken together, these
data suggest that the severe disturbance of glucose metabo-
lism characteristic of fak/fak rats arises, at least in part, from
the absence of hypothalamic leptin/PI3K signaling and that
this effect is not dependent on changes of food intake or
body weight.417
A R T I C L EIn conclusion, our results suggest that reduced leptin/PI3K
signaling in the mediobasal hypothalamus is a major contributor
to the severe insulin resistance and glucose intolerance of lep-
tin-receptor-deficient Koletsky rats and that, even though key
energy homeostasis neurocircuitry is found in the same brain
area, the underlying mechanism is not secondary to changes
of energy balance. Taken together, these findings reveal a key
role for leptin-sensing hypothalamic neurons in the control of
glucose homeostasis and implicate neuronal PI3K signaling as
an important mediator of this effect.
Experimental procedures
Experimental animals
Adult male obese (fak/fak) Koletsky rats and lean (Fa/Fa) male littermates
(Vassar College, Poughkeepsie, New York) were generated from serial back-
crosses (N10 equivalent) of the fakmutation (also known as Koletsky, faf, f, or
cp) to the inbred rat strain LA/N. All animals were housed individually in a spe-
cific-pathogen-free environment, maintained in a temperature-controlled
room with a 12:12 hr light:dark cycle, and provided with ad libitum access
to water and standard laboratory chow (PMI Nutrition International Inc.,
Brentwood, Missouri) unless otherwise stated. All study protocols were ap-
proved by the Animal Care and Use Committee at the University of Washing-
ton and were conducted in accordance with NIH guidelines for the care and
use of animals.
Adenovirus microinjection and third-cerebral-ventricle injections
Adenovirus (Ad) expressing either mouse leprb (Ad-LEPR-B; 4.7 3 1012
pfu/ml), a constitutively active PKB mutant (Ad-PKB-CA; 2.4 3 1012 pfu/ml)
previously shown to increase cellular PKB signaling (Wrede et al., 2002), or
the reporter gene green fluorescent protein (Ad-GFP; 2.7 3 1012 pfu/ml)
were microinjected bilaterally into the ARC of fak/fak rats as previously de-
scribed (Morton et al., 2003, 2005). For adenoviral localization, an adenoviral
construct containing leprb that also expresses the reporter gene GFP (Ad-
LEPR-B-GFP; 3.4 3 1012 pfu/ml) was used. Adenovirus was delivered at
a rate of 100 nl/min for 5 min (500 nl per injection site), and the injector and
cannula were removed 5 min after injections were completed. The regional
localization of adenovirally encoded proteins has been characterized in the
Results section and our previous studies (Morton et al., 2003, 2005), in which
we demonstrated that the ARC is successfully targeted in >80% of animals;
that adenoviral expression outside the ARC is observed in <25% of animals;
and that, when present, this expression is limited to the cannula tract (Morton
et al., 2005). In a subset of animals, an indwelling stainless-steel cannula was
inserted into the third cerebral ventricle (3V) at the time of adenovirus micro-
injection using an established technique (Schwartz et al., 1992) to determine
whether infusion of a PI3K inhibitor can reverse the metabolic benefit con-
ferred by restored hypothalamic leptin signaling.
Adenovirus localization
Seven days following ARC-directed microinjection of either Ad-GFP (n = 8) or
Ad-LEPR-B-GFP (n = 4), animals were anesthetized with ketamine/xylazine
and perfused with phosphate-buffered saline (PBS) followed by 4% parafor-
maldehyde (PFA) in 0.1 M PBS. Brains were removed, postfixed in 4% PFA
overnight, embedded in 25% sucrose solution for 48 hr at 4ºC, snap frozen
in isopentane cooled with liquid nitrogen, sectioned at 14 mM in a freezing
cryotome, slide mounted, and stored at 280ºC before visualization of GFP
by fluorescence microscopy. Images were captured using a Nikon Eclipse
e600 upright microscope (Nikon Inc., Melville, New York).
Food restriction and pair-feeding studies
To determine if increased food intake and body weight are required for insulin
resistance in animals lacking leptin receptors, we studied three groups of
8-week-old male Fa/Fa and fak/fak rats. Two of the groups (one of each
genotype) were fed ad libitum, while a second group of fak/fak rats were
restricted to 60% of their average daily food intake for a 2 week period pre-
dicted to reduce their body weight to that of lean littermates. Energy-
restricted animals were provided food in two equal portions, both at the onset
of and 4 hr into the dark cycle, and bodyweight wasmeasured daily. In a sep-
arate experiment, we controlled for the effects of restored hypothalamic lep-418tin signaling on body weight and food intake by pair feeding a group of fak/fak
rats that received ARC-directed delivery of control adenovirus (Ad-GFP) to
the intake of animals receiving leptin-receptor gene therapy. Prior to pair
feeding, animals in the two groups were matched for age, food intake,
body weight, and baseline glucose and insulin tolerance. Pair-fed rats were
provided two daily meals of equal size (3 hr before and 4 hr after dark-cycle
onset) such that the total amount of food provided was equal to that con-
sumed on the previous day by a previously assigned partner in the Ad-
LEPR-B group.
Measures of glucose tolerance and insulin tolerance
Insulin sensitivity was measured by intraperitoneal insulin-tolerance testing
(itt) following a 4 hr fast. In animals receiving adenoviral gene therapy, these
studies were performed both prior to and 7 days after adenoviral injection.
Following an i.p. injection of insulin (Humulin R; Lilly, Indianapolis, Indiana),
blood glucose levels were determined at t = 0, 30, 60, 90, and 120 min using
a hand-held glucometer (Accu-Chek; Roche Diagnostics, Indianapolis, Indi-
ana). Intraperitoneal glucose-tolerance tests (i.p. gtt) were also conducted
following an overnight fast both before and 7 days after adenoviral injection.
Following an i.p. injection of 30% D-glucose (2.5 g/kg) (Abbott Laboratories,
North Chicago, Illinois), glucose levels weremeasured in blood obtained from
the tail vein at t = 0, 30, 60, 90, and 120 min as described above. The insulin-
sensitivity index (ISI) was calculated from data obtained during the i.p. gtt ac-
cording to the formula ISI = 10,000/square root of ([fasting blood glucose
(mg/dl) 3 fasting plasma insulin (mU/ml)] 3 [blood glucose at t = 30 min
(mg/dl) 3 plasma insulin at t = 30 min (mU/ml)]) (Matsuda and DeFronzo,
1999). The area under the curve (AUC) and inverse area under the curve were
calculated using the trapezoid rule during the i.p. gtt and itt, respectively.
Effect of i.c.v. infusion of a PI3K inhibitor on insulin sensitivity
Seven days following ARC-directed microinjection of either Ad-GFP or Ad-
LEPR-B, obese fak/fak rats received an i.c.v. injection of the PI3K inhibitor
LY294002 (1 nmol) (Calbiochem, EMD Biosciences Inc., San Diego, Califor-
nia) or its vehicle 1 hr prior to conducting an itt, in a randomized crossover
design separated by at least 48 hr.
Plasma assays
Blood glucose was measured using a hand-held glucometer (Accu-Chek;
Roche Diagnostics) on blood obtained from tail capillary samples. Whole
blood was centrifuged at 1500 rpm for 30 min, and plasma was removed
and stored at220ºC. Plasma immunoreactive insulin levels were determined
by ELISA (Crystal Chem Inc., Chicago). Plasma triglyceride concentrations
were assessed by a fully enzymatic colorimetric assay after the removal of
free glycerol (Roche Diagnostics). Nonesterified fatty acids were measured
using a colorimetric assay kit that relies on fatty acids as substrate for enzy-
matic acylation of CoA (WAKO Chemicals USA Inc., Richmond, Virginia).
Plasma corticosterone levels were determined by radioimmunoassay (Diag-
nostic Production Corporation, Los Angeles). Plasma samples for insulin, tri-
glyceride, and free-fatty-acid analysiswere drawn from4 hr fasted rats treated
with Ad-GFP and either fed ad libitum or pair fed or with Ad-LEPR-B just prior
to conducting an itt. Plasma corticosterone levels were measured from the
same animals that were fasted overnight.
Statistical analysis
All results are expressed as mean 6 SEM. Statistical analyses were per-
formed using Statistical Package for the Social Sciences (SPSS version
10.1; SPSS Inc., Fullerton, California). A one-way analysis of variance with
a LSD post hoc test was used to compare means between multiple groups.
For two-group comparisons, a two-sample unpaired Student’s t test was
used, while a paired Student’s t test was employed for within-group compar-
isons. In all instances, probability values of <0.05were considered significant.
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